- Wondering whether Adaptive Biotechnologies at US$12.71 is priced attractively or not? This article unpacks what that tag could really mean for you.
- The stock has been under pressure in the short term, with the share price down 6.1% over the past week, 12.2% over the past month, and 20.1% year to date, even though the 1 year return is 38.2% and the 3 year return is 99.5% against a 65.3% decline over 5 years.
- Recent company specific news has put the focus back on how the business is positioned and what investors are currently willing to pay for that profile. This backdrop helps explain why the stock has seen both periods of strong gains and sharp pullbacks as the market reassesses the balance between potential and risk.
- Based on Simply Wall St's six point checklist, Adaptive Biotechnologies currently has a valuation score of 3 out of 6. Next, you will see how different methods such as DCF, multiples, and asset based views stack up, and then finish with a way to frame valuation that goes beyond the numbers alone.
Approach 1: Adaptive Biotechnologies Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today in dollar terms. For Adaptive Biotechnologies, the 2 Stage Free Cash Flow to Equity model starts from the latest twelve month free cash flow, which shows a loss of about $33.8 million.
Analysts provide free cash flow estimates out to 2029, with Simply Wall St extrapolating beyond that to build a 10 year path. In this framework, projected free cash flow for 2029 is $91 million, with later years rising into the low hundreds of millions according to the supplied projections. These future figures are discounted back to today and summed to reach an estimated intrinsic value per share of about $21.55.
Compared with the current share price of $12.71, the DCF output suggests the stock trades at a 41.0% discount, which indicates undervaluation based on this model alone.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Adaptive Biotechnologies is undervalued by 41.0%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.
Approach 2: Adaptive Biotechnologies Price vs Sales
For companies where profits are limited or volatile, investors often lean on the Price to Sales, or P/S, ratio, because revenue tends to be more stable and less affected by accounting choices than earnings.
The level of P/S that might be considered normal for a stock usually reflects what investors expect for future growth and how much risk they see in the business. Higher expected growth and lower perceived risk often line up with a higher P/S ratio, while slower growth or higher risk tend to go with a lower multiple.
Adaptive Biotechnologies currently trades on a P/S of 6.89x. This sits above the Life Sciences industry average of 3.49x and above the peer group average of 6.25x. Simply Wall St also provides a Fair Ratio of 3.80x. This Fair Ratio is a proprietary estimate of what P/S might be reasonable given factors such as the company’s earnings growth profile, profit margins, industry, market cap and key risks. Because it adjusts for these company specific drivers, it can be more useful than relying only on broad industry or peer comparisons.
Comparing the Fair Ratio of 3.80x with the current 6.89x suggests the stock screens as overvalued on this measure.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your Adaptive Biotechnologies Narrative
Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in: a simple tool on Simply Wall St's Community page that lets you connect your view of Adaptive Biotechnologies to concrete numbers by linking a story about the business to assumptions for future revenue, earnings and margins. These then roll into a fair value that you can compare with the current share price to help frame when you might buy or sell, and they update automatically when new news or earnings arrive. For example, one investor might build a cautious Narrative that aligns more with the US$18.00 analyst price target and focuses on risks such as ongoing losses and partnership reliance. Another investor might build a more optimistic Narrative closer to the US$22.00 high target that leans on expectations for MRD revenue, margin improvement and future cash flows. Seeing these side by side can help you decide which story feels more realistic for your own portfolio.
Do you think there's more to the story for Adaptive Biotechnologies? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com